Alida writes:

I really enjoy listening to the weekly update on “This week in virology” but I was very curious when I heard you say it is a must to aspirate before injecting an IM.

In Canada, we have not done this practice for more than 20 years. I started nursing school in 2000 and I have never aspirated and I have given thousands of vaccines and injections.

The CDC does not recommend aspiration before injection.

https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html#:~:text=Aspiration%20before%20injection%20of%20vaccines,painful%20for%20infants%20(20).

Just my thoughts!

Alida Fernhout, RN, MPH

Deepa writes:

Dear Dr. Griffin: I have been advised by my most excellent rheumatologist to skip 2 doses of Methotrexate after taking any vaccine (including the one for SAR-CoV-2) based on the attached publication.

This is the first study that I am aware of, that carefully evaluated the immune response to the flu vaccine in RA patients. They randomized to 2 cohorts – one that skipped 2 doses of Methotrexate and one that did not. There is a quite a remarkable and significant difference in the antibody response elicited – in favor of skipping Methotrexate. The key finding  – MTX discontinuation for 2 weeks after vaccination significantly increases the immunogenicity of a seasonal influenza vaccine in patients with RA, who had been on a stable dose of MTX, without significantly increasing risk of disease activity.

I hope this is helpful to you, your patients and listeners to this podcast. Not many people are aware of this study. We need more studies like this.

As a Ph.D. immunologist and a biotech investor and entrepreneur, I really appreciate your science first approach. Thank you also to the awesome Twiv team, particularly Dr. Vincent Racaniello.

Regards

Deepa

He sent: Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial https://pubmed.ncbi.nlm.nih.gov/29572291/ 

MaryAnn writes:

Hi Dr. Griffin,

I received my 1st dose of the Pfizer vaccine on March 23rd. At the time that I signed up for that vaccine, Walgreens had us schedule the second dose 4 weeks out, and my next dose is scheduled for April 20th, which is 28 days from the first dose.

I found out yesterday, via the NYTimes (https://www.nytimes.com/live/2021/04/05/world/covid-vaccine-coronavirus-cases#walgreens-covid-vaccine-doses) that Walgreens had taken it upon themselves to schedule these second doses at their “convenience” rather than at the tested interval, which should be 3 weeks/21 days. It never even occurred to me that it would be wrong.

Walgreens is being difficult to deal with, and will not allow the second dose to be rescheduled until 20 days after the first dose…the day before dose 2 is actually due. They are now telling customers that the CDC said that 28 days was just fine, and they approved it. Of course, according to reporting, the CDC says no such thing, though they do say that the vaccine should be ok any time in the 3-6 week window, even though that is not the researched interval, if it can’t be scheduled on time. Walgreens certainly isn’t taking any accountability for this screw up. It shouldn’t have been up to them to make this scheduling decision. I’m angry, and I’ll never spend another dime in their chain ever.

I am trying to get my second dose through another source, to bring it closer to the 3 week time frame, but so far no luck. With the phases opening to more people, there are even fewer vaccine slots available, local health departments have either Moderna or J&J (so that doesn’t help), and I suspect that I will simply need to keep the appointment for the 2nd dose at the 28 day mark. Now, of course, I lack some confidence in this, and I suffer from extreme “white coat” anxiety, so this makes it even worse.

So, any advice? Should I be looking at a booster sooner rather than later? Should I be asking my doctor for antibody testing? What can I do to feel better about this situation? I was looking forward to getting out of my house again. Now I feel unsure again. I figure I’ll be wearing a mask forever. 

In a time when my anxiety has been over the moon, thank you (and the whole TWiV team) for being a calm place to find accurate information. You guys get an A++. Walgreens gets an F-. 

Regards—

MaryAnne
Williamsburg, VA

TWiV 1027: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the transmission of SARS-CoV-2 in free-ranging white-tailed deer in the United States, Omicron subvariant BA.5 efficiently infects lung cells, COVID-19 scent dog research highlights and synthesis during the pandemic of December 2019, T-Cell Immunity against SARS-CoV-2 measured by an interferon-γ release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants, a common allele of HLA is associated with asymptomatic SARS-CoV-2 infection, and the immunology of long COVID. Read more

TWiV 1025: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the new risk assessment for the H5N1 avian flu viruses, the development of monoclonal antibody-based blocking ELISA for detecting SARS-CoV-2 exposure in animals, repeated antibiotic exposure and risk of hospitalization and death following COVID-19 infection, COVID-19 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with Nirmatrelvir plus Ritonavir versus untreated controls, exaggerated blood pressure elevation in response to orthostatic challenge a post-acute sequelae of SARS-CoV-2 infection (PASC) after hospitalization, long term follow-up of a multicenter cohort of COVID-19 patients with pulmonary embolism, and risk of cardiovascular disease after COVID‐19 diagnosis among adults with and without diabetes. Read more

TWiV 1024: The Chumakoviridae

Vincent speaks with Kostya Chumakov about his career: raised by two virology parents in Moscow, trained in virology by Vadim Agol, then moving to the US FDA where he developed a molecular test for measuring production consistency of oral poliovirus vaccine. Read more

TWiV 1022: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses autochthonous leprosy in the United States, a systematic review to identify novel clinical characteristics of Mpox virus infection and therapeutic and preventive strategies to combat the virus, two-year duration of immunity of inactivated poliovirus vaccine, evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 Infection, effectiveness of the COVID-19 bivalent vaccine, oral Nirmatrelvir and Ritonavir for COVID-19 in vaccinated, non-hospitalized adults ages 18-50 years, genome-wide association study of long COVID, vaccination ameliorates cellular inflammatory responses in SARS-CoV-2 breakthrough infections, and high incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long-COVID. Read more

TWiV 1020: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses guidance on measles during the summer travel season, the Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing, SARS-CoV-2 variants and age-dependent infection rates among household and nonhousehold contacts, effect of COVID-19 vaccination on household transmission of SARS-COV-2 in the Omicron era, incidence of myopericarditis after mRNA COVID-19 vaccination, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong, safety, immunogenicity and protection of heterologous boost with an aerosolized Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults, awake prone positioning for non-intubated patients with COVID-19-related acute hypoxic respiratory failure, melatonin effects on sleep quality of COVID-19 patients, female reproductive health impacts of Long COVID and associated illnesses including ME/CFS, POTS, and connective tissue disorders, and incident autoimmune diseases in association with SARS-CoV-2 infection. Read more

TWiV 1018: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the CDC vaccine advisory group recommending the newly approved RSV vaccines, association of culturable-virus detection and household transmission of SARS-CoV-2, prevention of COVID-19 following a single intramuscular administration of Adintrevimab, real-world effectiveness of Nirmatrelvir/Ritonavir on COVID-19, and COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization. Read more